Innate Pharma S.A.
IPH.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €118 | €160 | €200 | €271 |
| - Cash | €66 | €71 | €84 | €104 |
| + Debt | €31 | €40 | €42 | €44 |
| Enterprise Value | €82 | €129 | €158 | €211 |
| Revenue | €13 | €52 | €50 | €12 |
| % Growth | -75.7% | 4.6% | 309.8% | – |
| Gross Profit | -€32 | €6 | €6 | -€35 |
| % Margin | -252.4% | 10.8% | 12.1% | -288.1% |
| EBITDA | -€51 | -€2 | -€61 | -€43 |
| % Margin | -404% | -3.5% | -123.5% | -356.9% |
| Net Income | -€49 | -€8 | -€58 | -€53 |
| % Margin | -391.9% | -14.6% | -117.1% | -436% |
| EPS Diluted | -0.61 | -0.094 | -0.73 | -0.66 |
| % Growth | -548.2% | 87.1% | -10.6% | – |
| Operating Cash Flow | -€7 | -€33 | -€19 | -€58 |
| Capital Expenditures | -€0 | -€2 | -€1 | -€1 |
| Free Cash Flow | -€7 | -€35 | -€20 | -€60 |